There is currently only one published randomised trial (LUX-Lung 3) that compares a TKI (afatinib) with pemetrexed-based chemotherapy for the first-line treatment of advanced EGFR mutation positive NSCLC [6]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.